GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Sophia Genetics SA (NAS:SOPH) » Definitions » EV-to-FCF

Sophia Genetics (Sophia Genetics) EV-to-FCF : -3.86 (As of May. 12, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Sophia Genetics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sophia Genetics's Enterprise Value is $220.32 Mil. Sophia Genetics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-57.08 Mil. Therefore, Sophia Genetics's EV-to-FCF for today is -3.86.

The historical rank and industry rank for Sophia Genetics's EV-to-FCF or its related term are showing as below:

SOPH' s EV-to-FCF Range Over the Past 10 Years
Min: -23.19   Med: -2.14   Max: 1.01
Current: -3.86

During the past 6 years, the highest EV-to-FCF of Sophia Genetics was 1.01. The lowest was -23.19. And the median was -2.14.

SOPH's EV-to-FCF is ranked worse than
100% of 365 companies
in the Healthcare Providers & Services industry
Industry Median: 19.37 vs SOPH: -3.86

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-12), Sophia Genetics's stock price is $4.69. Sophia Genetics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.120. Therefore, Sophia Genetics's PE Ratio for today is At Loss.


Sophia Genetics EV-to-FCF Historical Data

The historical data trend for Sophia Genetics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sophia Genetics EV-to-FCF Chart

Sophia Genetics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial - - -10.03 0.37 -3.50

Sophia Genetics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.27 -2.38 -0.88 -3.50 -4.13

Competitive Comparison of Sophia Genetics's EV-to-FCF

For the Health Information Services subindustry, Sophia Genetics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sophia Genetics's EV-to-FCF Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Sophia Genetics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Sophia Genetics's EV-to-FCF falls into.



Sophia Genetics EV-to-FCF Calculation

Sophia Genetics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=220.316/-57.082
=-3.86

Sophia Genetics's current Enterprise Value is $220.32 Mil.
Sophia Genetics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-57.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sophia Genetics  (NAS:SOPH) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Sophia Genetics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=4.69/-1.120
=At Loss

Sophia Genetics's share price for today is $4.69.
Sophia Genetics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.120.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Sophia Genetics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Sophia Genetics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Sophia Genetics (Sophia Genetics) Business Description

Traded in Other Exchanges
Address
Rue du Centre 172, Saint-Sulpice, CHE, CH-1025
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities.